TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis

European Journal of Immunology

Volumn 43, Issue 12, 2013, Pages 3138-3146

  Flutter, Barry ^a   Nestle, Frank O ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Animal models; Imiquimod; Psoriasis; TLR7

Indexed keywords

ADENOSINE RECEPTOR; CYTOKINE; IMIQUIMOD; INFLAMMASOME; INTERLEUKIN 23; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; TLR8 PROTEIN, HUMAN;

ARTICLE; DERMIS; DRUG MECHANISM; HUMAN; INFLAMMATION; INNATE IMMUNITY; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; ANIMAL MODELS; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG POTENTIATION; IMMUNOLOGY; MOUSE; PATHOLOGY;

ANIMAL MODELS; IMIQUIMOD; PSORIASIS; TLR7;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; PSORIASIS; RECEPTORS, PURINERGIC P1; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84896320691     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343801     Document Type: Article

References (61)

1. Nestle, F. O., Di Meglio, P., Qin, J. Z. and Nickoloff, B. J., Skin immune sentinels in health and disease. Nat. Rev. Immunol. 2009. 9: 679-691.
2. Gudjonsson, J. E., Johnston, A., Dyson, M., Valdimarsson, H. and Elder, J. T., Mouse models of psoriasis. J. Invest. Dermatol. 2007. 127: 1292-1308.
3. Boyman, O., Hefti, H. P., Conrad, C., Nickoloff, B. J., Suter, M. and Nestle, F. O., Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 2004. 199: 731-736.
4. van der Fits, L., Mourits, S., Voerman, J. S., Kant, M., Boon, L., Laman, J. D., Cornelissen, F. et al., Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 2009. 182: 5836-5845.
5. Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Schafer, M., Coyle, A. J., Renauld, J. C. et al., Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Invest. 2012. 122: 3965-3976.
6. Pantelyushin, S., Haak, S., Ingold, B., Kulig, P., Heppner, F. L., Navarini, A. A. and Becher, B., Rorgammat +innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 2012. 122: 2252-2256.
7. Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R. et al., Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011. 35: 596-610.
8. Walter, A., Schafer, M., Cecconi, V., Matter, C., Urosevic-Maiwald, M., Belloni, B., Schonewolf, N. et al., Aldara activates TLR7-independent immune defence. Nat. Commun. 2013. 4: 1560.
9. Nestle, F. O., Kaplan, D. H. and Barker, J., Psoriasis. N. Engl. J. Med. 2009. 361: 496-509.
10. Wang, H., Kess, D., Lindqvist, A. K., Peters, T., Sindrilaru, A., Wlaschek, M., Blakytny, R. et al., A 9-centimorgan interval of chromosome 10 controls the T cell-dependent psoriasiform skin disease and arthritis in a murine psoriasis model. J. Immunol. 2008. 180: 5520-5529.
11. Zenz, R., Eferl, R., Kenner, L., Florin, L., Hummerich, L., Mehic, D., Scheuch, H. et al., Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005. 437: 369-375.
12. Chollet, J. L., Jozwiakowski, M. J., Phares, K. R., Reiter, M. J., Roddy, P. J., Schultz, H. J., Ta, Q. V. et al., Development of a topically active imiquimod formulation. Pharm. Dev. Technol. 1999. 4: 35-43.
13. Harrison, C. J., Jenski, L., Voychehovski, T. and Bernstein, D. I., Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res. 1988. 10: 209-223.
14. Edwards, L., Ferenczy, A., Eron, L., Baker, D., Owens, M. L., Fox, T. L., Hougham, A. J. et al., Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch. Dermatol. 1998. 134: 25-30.
15. Beutner, K. R., Spruance, S. L., Hougham, A. J., Fox, T. L., Owens, M. L. and Douglas, J. M., Jr., Treatment of genital warts with an immune-response modifier (imiquimod). J. Am. Acad. Dermatol. 1998. 38: 230-239.
16. Sidky, Y. A., Borden, E. C., Weeks, C. E., Reiter, M. J., Hatcher, J. F. and Bryan, G. T., Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 1992. 52: 3528-3533.
17. Beutner, K. R., Geisse, J. K., Helman, D., Fox, T. L., Ginkel, A. and Owens, M. L., Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J. Am. Acad. Dermatol. 1999. 41: 1002-1007.
18. Hadley, G., Derry, S. and Moore, R. A., Imiquimod for actinic keratosis: systematic review and meta-analysis. J. Invest. Dermatol. 2006. 126: 1251-1255.
19. Falagas, M. E., Angelousi, A. G. and Peppas, G., Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J. Am. Acad. Dermatol. 2006. 55: 537-538.
20. Drobits, B., Holcmann, M., Amberg, N., Swiecki, M., Grundtner, R., Hammer, M., Colonna, M. et al., Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 2012. 122: 575-585.
21. Palamara, F., Meindl, S., Holcmann, M., Luhrs, P., Stingl, G. and Sibilia, M., Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. 2004. 173: 3051-3061.
22. Wohn, C., Ober-Blobaum, J. L., Haak, S., Pantelyushin, S., Cheong, C., Zahner, S. P., Onderwater, S. et al., Langerinneg conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc. Natl. Acad. Sci. U S A 2013. 110: 10723-10728.
23. Van Belle, A. B., de Heusch, M., Lemaire, M. M., Hendrickx, E., Warnier, G., Dunussi-Joannopoulos, K., Fouser, L. A. et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J. Immunol. 2012. 188: 462-469.
24. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T. et al., Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002. 3: 196-200.
25. Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G. et al., Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002. 3: 499.
26. Larange, A., Antonios, D., Pallardy, M. and Kerdine-Romer, S., TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J. Leukoc. Biol. 2009. 85: 673-683.
27. Kanneganti, T. D., Ozoren, N., Body-Malapel, M., Amer, A., Park, J. H., Franchi, L., Whitfield, J. et al., Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006. 440: 233-236.
28. Kollisch, G., Kalali, B. N., Voelcker, V., Wallich, R., Behrendt, H., Ring, J., Bauer, S. et al., Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 2005. 114: 531-541.
29. Schon, M. P., Schon, M. and Klotz, K. N., The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J. Invest. Dermatol. 2006. 126: 1338-1347.
30. Schon, M., Bong, A. B., Drewniok, C., Herz, J., Geilen, C. C., Reifenberger, J., Benninghoff, B. et al., Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl. Cancer Inst. 2003. 95: 1138-1149.
31. Schon, M. P. and Schon, M., Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004. 9: 291-298.
32. Suzuki, H., Wang, B., Shivji, G. M., Toto, P., Amerio, P., Tomai, M. A., Miller, R. L. et al., Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Invest. Dermatol. 2000. 114: 135-141.
33. Ramirez-Carrozzi, V., Sambandam, A., Luis, E., Lin, Z., Jeet, S., Lesch, J., Hackney, J. et al., IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 2011. 12: 1159-1166.
34. Boniface, K., Bernard, F. X., Garcia, M., Gurney, A. L., Lecron, J. C. and Morel, F., IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 2005. 174: 3695-3702.
35. Heib, V., Becker, M., Warger, T., Rechtsteiner, G., Tertilt, C., Klein, M., Bopp, T. et al., Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 2007. 110: 946-953.
36. Cho, K. A., Suh, J. W., Lee, K. H., Kang, J. L. and Woo, S. Y., IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1beta by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int. Immunol. 2012. 24: 147-158.
37. Uribe-Herranz, M., Lian, L. H., Hooper, K. M., Milora, K. A. and Jensen, L. E., IL-1R1 signaling facilitates Munro's microabscess formation in psoriasiform imiquimod-induced skin inflammation. J. Invest. Dermatol. 2013. 133: 1541-1549.
38. Johnston, A., Xing, X., Guzman, A. M., Riblett, M., Loyd, C. M., Ward, N. L., Wohn, C. et al., IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 2011. 186: 2613-2622.
39. Greter, M., Lelios, I., Pelczar, P., Hoeffel, G., Price, J., Leboeuf, M., Kundig, T. M. et al., Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity 2012. 37: 1050-1060.
40. Sutton, C. E., Mielke, L. A. and Mills, K. H., IL-17-producing gammadelta T cells and innate lymphoid cells. Eur. J. Immunol. 2012. 42: 2221-2231.
41. Gilliet, M., Conrad, C., Geiges, M., Cozzio, A., Thurlimann, W., Burg, G., Nestle, F. O. et al., Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 2004. 140: 1490-1495.
42. Chen, K., Yap, L. M., Marks, R. and Shumack, S., Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas. J. Dermatol. 2003. 44: 250-255.
43. Swindell, W. R., Johnston, A., Carbajal, S., Han, G., Wohn, C., Lu, J., Xing, X. et al., Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One 2011. 6: e18266.
44. Croxford, A. L., Mair, F. and Becher, B., IL-23: one cytokine in control of autoimmunity. Eur. J. Immunol. 2012. 42: 2263-2273.
45. Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P. et al., Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 2008. 128: 1207-1211.
46. Wolk, K., Witte, E., Wallace, E., Docke, W. D., Kunz, S., Asadullah, K., Volk, H. D. et al., IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 2006. 36: 1309-1323.
47. Onoufriadis, A., Simpson, M. A., Pink, A. E., Di Meglio, P., Smith, C. H., Pullabhatla, V., Knight, J et al., Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 2011. 89: 432-437.
48. Khor, B., Gardet, A. and Xavier, R. J., Genetics and pathogenesis of inflammatory bowel disease. Nature 2011. 474: 307-317.
49. Gao, Z., Tseng, C. H., Strober, B. E., Pei, Z. and Blaser, M. J., Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One 2008. 3: e2719.
50. Naik, S., Bouladoux, N., Wilhelm, C., Molloy, M. J., Salcedo, R., Kastenmuller, W., Deming, C. et al., Compartmentalized control of skin immunity by resident commensals. Science 2012. 337: 1115-1119.
51. Köbner, H., Zur Aetiologie der Psoriasis. Vrtljscher Dermatol. Syphil. 1876. 8: 559-561.
52. Tsoi, L. C., Spain, S. L., Knight, J., Ellinghaus, E., Stuart, P. E., Capon, F., Ding, J. et al., Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 2012. 44: 1341-1348.
53. Tiilikainen, A., Lassus, A., Karvonen, J., Vartiainen, P. and Julin, M., Psoriasis and HLA-Cw6. Br. J. Dermatol. 1980. 102: 179-184.
54. Laggner, U., Di Meglio, P., Perera, G. K., Hundhausen, C., Lacy, K. E., Ali, N., Smith, C. H. et al., Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J. Immunol. 2011. 187: 2783-2793.
55. Kaffenberger, B. H., Wong, H. K., Jarjour, W. and Andritsos, L. A., Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation. J. Am. Acad. Dermatol. 2013. 68: 489-492.
56. Bernink, J. H., Peters, C. P., Munneke, M.,Velde, A. A., Meijer, S. L., Weijer, K., Hreggvidsdottir, H. S. et al., Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 2013. 14: 221-229.
57. Villanova, F., Flutter, B., Tosi, I., Grys, K., Sreeneebus, H., Perera, G. K., Chapman, A. et al., Characterization of innate lymphoid cells (ILC) in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J. Invest. Dermatol. 2013. In Press.
58. Nestle, F. O., Turka, L. A. and Nickoloff, B. J., Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 1994. 94: 202-209.
59. Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G. et al., Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 2005. 202: 135-143.
60. Becker, M., Heib, V., Klein, M., Doener, F., Bopp, T., Taube, C., Radsak, M. et al., Impaired mast cell-driven immune responses in mice lacking the transcription factor NFATc2. J. Immunol. 2009. 182: 6136-6142.
61. Ishizaki, M., Akimoto, T., Muromoto, R., Yokoyama, M., Ohshiro, Y., Sekine, Y., Maeda, H. et al., Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J. Immunol. 2011. 187: 181-189.